Spring Discovery

Spring Discovery is a company that develops a computational drug discovery platform for age-related diseases. It was established by Ben Kamens in 2017. It has received funding from investors such as General Catalyst, First Round Capital, and Village Global. The company is headquartered in Palo Alto, California, United States. Spring Discovery also operates a laboratory for experimental purposes in San Carlos, California.

Spring Discovery's platform is intended to reduce the time needed for drug development during the preclinical trial phase. The platform aims to develop therapeutics that have been proven by prior research to have a significant positive impact on longevity as tested on mice. These include the use of compounds such as cyclophilin D and myostatin inhibitors, which were developed to treat neurodegeneration and Duchenne muscular dystrophy (DMD) respectively. The platform is supposed to combine biology, machine learning, and lab automation to achieve this purpose.